États-Unis · Bourse & Finance · The Motley Fool

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.

Publié par The Motley Fool · États-Unis il y a 11 h

Viking Therapeutics tested various doses of its leading anti-obesity candidate, VK2735, administered subcutaneously every other week or monthly (VK2735 also mimics the action of…

Lire l'article complet sur The Motley Fool Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.fool.com)

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.

À lire aussi

MetaMask exits Lido validators as it investigates security incident

Read the letter Trump is sending along with $500 checks to nearly 1 million Americans for ACA 'refunds'

Iran’s Disappearing Oil Is Becoming Everyone’s Problem

Google releases Gemini 4 Argon, called its most powerful model yet

Transocean gets DOJ approval for Valaris acquisition

Bessent Settled Tax Issue That Had Put Him at Odds With I.R.S.

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.

Partager

À lire aussi

MetaMask exits Lido validators as it investigates security incident

Read the letter Trump is sending along with $500 checks to nearly 1 million Americans for ACA 'refunds'

Iran’s Disappearing Oil Is Becoming Everyone’s Problem

Google releases Gemini 4 Argon, called its most powerful model yet

Transocean gets DOJ approval for Valaris acquisition

Bessent Settled Tax Issue That Had Put Him at Odds With I.R.S.